Advances in Precision Medicine for Gynecologic Cancers: Clinical Application for Nursing Practice

Join us for this 1-hour CE-certified webinar featuring nursing perspectives for managing patients with cervical, endometrial, and ovarian cancers, including information on predictive biomarkers and key clinical trial data from  recent approvals. 

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


Welcome and Introduction

Genetic Drivers of Cervical, Endometrial, and Ovarian Oncogenesis and Their Role in Therapy Selection

Case Discussion: Recent Approvals and Expanded Indications in Treatment of Ovarian Cancer

Case Discussion: New Advances in Individualized Treatment for Endometrial Cancer

Case Discussion: Emerging Precision Medicine Data in Cervical Cancer

Supportive Care Challenges In Patients With Gynecologic Cancers and How to Overcome Them

Putting It All Together: Takeaway Points and Discussion of Available Online Resources and Tools


Date / Time
Event Details


Courtney Arn, CNP

CNP, Gynecologic Oncology
Women’s Health Nurse Practitioner, Gynecologic Oncology
The Ohio State University
Columbus, Ohio

Goal Statement
The goal of this activity is to improve oncology nurses’ ability to educate and optimally care for patients with gynecologic malignancies.

Target Audience
This program is intended for oncology nurses and other HCPs who care for patients with gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss with patients the available data surrounding the rationale for targeting predictive biomarkers in gynecologic malignancies
  • Counsel patients on the administration and potential toxicities of immune checkpoint inhibitors and PARP inhibitors as single-agent or combination therapies for the treatment of cervical, endometrial, and ovarian cancer
  • Describe available maintenance therapies for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Recognize and manage irAEs in patients receiving immune checkpoint inhibitor therapy
  • Develop a proactive management plan to support adherence in patients receiving oral PARP inhibitor therapy


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.